

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**HARBOUR**  
BIOMED

和 鉑 醫 藥 控 股 有 限 公 司

**HBM Holdings Limited**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 02142)**

**VOLUNTARY ANNOUNCEMENT**  
**U.S. FDA IND CLEARANCE FOR HBM7004 FOR THE TREATMENT OF**  
**ADVANCED SOLID TUMORS**

This announcement is made by HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Company has received clearance of its Investigational New Drug (“**IND**”) application from the Food and Drug Administration of the United States (the “**FDA**”) to initiate a first-in-human Phase I clinical trial in the U.S. for HBM7004, a novel B7H4xCD3 bispecific antibody. This is a Phase I study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of HBM7004 in subjects with advanced solid tumors.

**About HBM7004**

HBM7004 is a novel B7H4xCD3 bispecific antibody developed using the Group’s proprietary HBICE® platform. This bispecific antibody is designed to provide a differentiated approach to cancer immunotherapy with the potential to enhance both efficacy and safety. The development of HBM7004 further demonstrates the versatility and plug-and-play advantages of the HBICE® platform.

In preclinical studies, HBM7004 demonstrated intratumor B7H4-dependent T-cell activation. In multiple animal models, HBM7004 showed strong anti-tumor efficacy, remarkable *in vivo* stability, and reduced systemic toxicity. Additionally, in preclinical models, HBM7004 exhibited a strong synergistic effect when combined with a B7H4x4-1BB bispecific antibody at a low effector-to-target cell ratio, indicating an encouraging therapeutic window.

**Cautionary Statement:** We cannot guarantee that we will be able to successfully develop or ultimately market HBM7004. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board  
**HBM Holdings Limited**  
**Dr. Jingsong Wang**  
*Chairman and Executive Director*

Hong Kong, 8 May 2026

*As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson and Ms. Weiwei Chen as independent non-executive Directors.*